等待开盘 08-15 09:30:00 美东时间
+1.400
+3.92%
Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses of $(22.28) per share from the same period last year. The company reported quarterly sales of $148.000...
08-13 19:29
今年美国首次公开募股(IPO)市场的最大赢家并非人工智能(AI)企业,而是生物科技板块。受行业基本面改善、大型药企并购活跃以及资本持续流入推动,生物科技IPO表...
07-21 23:23
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-18 18:30
今日重点评级关注:Roth Capital:维持Nuvectis Pharma"买入"评级,目标价从20美元升至33美元;摩根士丹利:维持GXO Logistics"超配"评级,目标价从75美元升至78美元
07-07 11:34
B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.
07-06 18:29
生物制药股NUVL涨超35%,获葛兰素史克高额溢价收购;支付公司Payoneer涨超33%,获加拿大支付公司Nuvei收购;超微电脑跌超26%,70亿美元的股权融资引市场忧虑>>
06-13 09:46
临床阶段生物制药公司Parabilis Medicines本周完成了有史以来规模最大的风投支持生物科技首次公开募股,筹资约6.7亿美元,超出此前由Kail...
06-11 20:49
新股PBLS大涨58%,此前获10倍超购募资7.45亿美元;FAC大涨37%,近日完成SPAC合并登陆纳斯达克;凯西通用零售涨逾20%,Q4业绩超预期并大幅上调股息>>
06-11 16:35
雷递网 雷建平 6月11日 美国生物科技公司Parabilis Medicines(Nasdaq: PBLS)昨日在美国纳斯达克上市,发行价为20美元,发行3...
06-11 07:51